Gastroenterologist, IBD & depression research, somewhere on Dartmoor
Exeter, England
Joined January 2017
- Tweets645
- Following551
- Followers413
- Likes642
James Goodhand retweeted
Two differences… 1) I’m a great deal more handsom 2) I paid for them myself 😉
James Goodhand retweeted
Read an interesting paper on direct-to-public calprotectin testing
Article link: bit.ly/4cJnIcM
@JamesGoodhand1, @tariqahmadIBD, @DrNickKennedy, @clairebewshea, @exeteribdresea1
This looks like great fun!
Excited to take over the trainee section from @YazHaddadin (big shoes). An honour to co-chair endolive @Srisha_Hebbar with @gastro3570, @mariapellise1. Proud to see @Dr_Lewis_David on the big stage. Congrats to the BSG team and @TFILodestar #bsg2023 @BritSocGastro @BSGTrainees
James Goodhand retweeted
It's finally here. The moment. Let's go.
⏰ 11am (UK)
📺 @SkyCricket
📻 @bbctms
📲 ms.spr.ly/6012gUIzq
🏴 #ENGvAUS 🇦🇺
Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies... - goo.gl/scholar/aVxYYb #ScholarAlerts
Thanks (again) to all of IBD teams across the UK who contributed to PANTS.
James Goodhand retweeted
🔬Our Neurodegeneration #research theme focuses on testing new and better drugs for #dementia and other neurodegenerative diseases & developing new tests to improve early diagnosis.
🌐Learn about our work: bit.ly/3SZWfLc
@alzheimerssoc @Clive_Ballard @PsyEpigenetics
ALT Text: We'll use cutting-edge translational biomedical research and innovative clinical trial to develop new ways to treat neurodegenerative diseases like dementia and Parkinson's, keeping people at the heart of our research. Professor Jon Mill.
James Goodhand retweeted
Research from MDR's James Alexander @NickPowellLab & colleagues shows that immune responses to #COVID vaccinations in immunosuppressed patients with inflammatory bowel disease (#IBD) are associated with gut microbiota composition and function.
thelancet.com/journals/ebiom…
James Goodhand retweeted
Islet autoantibody level distribution in type 1 diabetes and their association with genetic and clinical characteristics. bit.ly/3BvD58Q @UofE_Research @ExeterMed
James Goodhand retweeted
Mark Caulfield presenting GEL experience at 2nd WEF/Tsinghau University Precision Medicine Summit in Beijing #GA4GH
James Goodhand retweeted
Drug commonly used to treat inflammatory bowel disease limits protection given by 3rd #COVID #vaccine dose, finds new study from @clarityibd
People on Infliximab were more than twice as likely to get a breakthrough infection.
Read the full story
👇
covidvaccineresearch.org/new…
James Goodhand retweeted
Results from the latest @clarityibd paper published in @Gut_BMJ summarised here:
This Post is from an account that no longer exists. Learn more
The key question now is - can we improve vaccine responses in patients treated with antiTNF drugs?
The latest @clarityibd paper "Vaccine escape, increased breakthrough and reinfection in IFX-treated patients with IBD during the Omicron wave of the #COVID19 pandemic" is online via bit.ly/3zC441w @DrNickKennedy, @nchanchlani1, @SimengLin, @JamesGoodhand1, @tariqahmadIBD
Case study: CLARITY IBD: Changing the way we do research | NIHR nihr.ac.uk/documents/case-st…
James Goodhand retweeted
They only went and WON 🏆 🍾GastroBigRoom @DPT_NHS @RDEhospitals recognised for integrated care @HSJptsafety Mental Health Initiative 👏👏👏
Drug level data from CLARITY IBD. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients | Journal of Crohn's and Colitis | Oxford Academic academic.oup.com/ecco-jcc/ad…
James Goodhand retweeted
Where the Magic happens for @VIPStudy1 #Edinburgh. @Gastro_GRJ @charlie_lees – at Edinburgh, Scotland
